Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 66 of 279 for:    Best Disease

Which Platelet Function Test Best Reflects the In Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite? (HARMONIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02690454
Recruitment Status : Completed
First Posted : February 24, 2016
Last Update Posted : August 17, 2016
Sponsor:
Information provided by (Responsible Party):
Marek Kozinski, Collegium Medicum w Bydgoszczy

Brief Summary:

Ticagrelor is a direct-acting, reversible platelet P2Y12 receptor inhibitor recommended by the recent European Society of Cardiology guidelines in patients with acute coronary syndromes (ACS) (class of recommendation I, level of evidence B). Ticagrelor inhibits platelet function stronger, faster and more consistently than clopidogrel, the former standard of antiplatelet therapy. In the landmark PLATO trial (Study of PLATelet inhibition and patient Outcomes), ticagrelor therapy as compared with clopidogrel treatment was associated with the reduced occurrence of major adverse cardiovascular events and all-cause mortality, but also resulted in a small, but statistically significant, increase in the rate of major bleeding. The optimum choice of antiplatelet treatment, aimed to provide each patient with maximum protection against ischemic events, while minimizing the risk of bleeding complications, is the challenge of contemporary ACS therapy. The tool which may help physicians and facilitate clinical decision making is platelet function testing. According to the guidance of both European and American groups of experts, there are three currently recommended platelet function tests, namely the VerifyNow device, the Multiplate analyzer and the Vasodilator Stimulated Phosphoprotein Phosphorylation (VASP) assay. It needs to be emphasized that none of these three methods is preferred over others. So far there are no studies linking pharmacokinetic analysis of ticagrelor and its active metabolite with comparative evaluation of platelet reactivity. The aim of this trial is to assess the relationship between concentrations of ticagrelor and its active metabolite (AR-C124910XX) and results of all three recommended platelet function tests in patients with myocardial infarction. Patients who receive GP IIb/IIIa receptor inhibitor will be excluded from the primary analysis.

Statistical analysis: The correlation will be assessed using correlation coefficients and intraclass correlation coefficients. while the agreement between the results of the compared platelet function tests will be measured using the Kappa statistic and Bland-Altman analysis.


Condition or disease
Infarction Myocardial Infarction Cardiovascular Diseases Heart Diseases Ischemia Myocardial Ischemia Necrosis Pathologic Processes Vascular Diseases

Layout table for study information
Study Type : Observational
Actual Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Which Platelet Function Test Provides the Best Reflection of the in Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite? A Pharmacokinetic and Pharmacodynamic Study Including Patients With Myocardial Infarction.
Study Start Date : November 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Ticagrelor




Primary Outcome Measures :
  1. Correlation coefficient between ticagrelor plasma concentration and platelet reactivity measurement [platelet reactivity index (PRI), platelet arbitrary aggregation units/min and P2Y12 Reaction Units (PRU)]. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess correlation coefficients in broad ranges of ticagrelor concentrations and values of platelet reactivity. Platelet reactivity measurements will be made immediately after blood sample collection. Ticagrelor plasma concentration will be assessed at the end of participant enrollment. From each study participant, 8 correlation coefficients (for eight sampling points) for each compared methods of platelet reactivity measurement will be included in the final analysis. Values of correlation coefficients will be compared among assessed methods of platelet reactivity measurement.

    Platelet reactivity measurements: platelet reactivity index (PRI) assessed by VASP/P2Y12 assay, platelet arbitrary aggregation units/min assessed by Multiple Electrode Aggregometry (Multiplate® ADPtest) and P2Y12 Reaction Units (PRU) assessed by VerifyNow® PRUTest™.



Secondary Outcome Measures :
  1. Correlation coefficient between ticagrelor active metabolite (AR-C124910XX) plasma concentration and platelet reactivity measurement [platelet reactivity index (PRI), platelet arbitrary aggregation units/min and P2Y12 Reaction Units (PRU)]. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess correlation coefficients in broad ranges of AR-C124910XX concentrations and values of platelet reactivity. Platelet reactivity measurements will be made immediately after blood sample collection. Active ticagrelor metabolite plasma concentration will be assessed at the end of participant enrollment. From each study participant, 8 correlation coefficients (for eight sampling points) for each compared methods of platelet reactivity measurement will be included in the final analysis. Values of correlation coefficients will be compared among assessed methods of platelet reactivity measurement at the end of participant enrollment.

    Platelet reactivity measurements: platelet reactivity index (PRI) assessed by VASP/P2Y12 assay, platelet arbitrary aggregation units/min assessed by Multiple Electrode Aggregometry (Multiplate® ADPtest) and P2Y12 Reaction Units (PRU) assessed by VerifyNow® PRUTest™.


  2. Correlation coefficient between ticagrelor plasma concentration and inhibition of platelet reactivity assessed with VASP assay, Multiplate® analyzer and VerifyNow® device). [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess correlation coefficients in broad ranges of ticagrelor concentrations and values of inhibition of platelet reactivity. From each study participant, 7 correlation coefficients (for inhibition of platelet reactivity 1, 2, 3, 4, 6, 12, 24 hours post dose) for each compared methods of platelet reactivity measurement will be included in the final analysis. Values of correlation coefficients will be calculated and compared among assessed methods of platelet reactivity measurement at the end of participant enrollment.

    Inhibition of platelet aggregation: predose platelet reactivity minus actual platelet reactivity divided by predose platelet reactivity.

    Platelet reactivity measurements: platelet reactivity index (PRI) assessed by VASP/P2Y12 assay, platelet arbitrary aggregation units/min assessed by Multiple Electrode Aggregometry (Multiplate® ADPtest) and P2Y12 Reaction Units (PRU) assessed by VerifyNow® PRUTest™.


  3. Correlation coefficient between ticagrelor active metabolite (AR-C124910XX) plasma concentration and inhibition of platelet reactivity assessed with VASP assay, Multiplate® analyzer and VerifyNow® device. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess correlation coefficients in broad ranges of AR-C124910XX concentrations and values of inhibition of platelet reactivity. From each study participant, 7 correlation coefficients (for inhibition of platelet reactivity 1, 2, 3, 4, 6, 12, 24 hours post dose) for each compared methods of platelet reactivity measurement will be included in the final analysis. Values of correlation coefficients will be calculated and compared among assessed methods of platelet reactivity measurement at the end of participant enrollment.

    Inhibition of platelet aggregation: predose platelet reactivity minus actual platelet reactivity divided by predose platelet reactivity.

    Platelet reactivity measurements: platelet reactivity index (PRI) assessed by VASP/P2Y12 assay, platelet arbitrary aggregation units/min assessed by Multiple Electrode Aggregometry (Multiplate® ADPtest) and P2Y12 Reaction Units (PRU) assessed by VerifyNow® PRUTest™.


  4. Kappa statistics assessing agreement between the platelet reactivity measurements performed with the VASP assay and the Multiplate® and VerifyNow® assays in terms of identification of patients with high on-ticagrelor platelet reactivity. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]
    Blood samples will be collected in multiple time points in order to assess a broad range of platelet reactivity values. From each study participant, eight measurements of platelet reactivity (for all sampling points) for each compared methods will be included in the final analysis.The Kappa statistics values will be calculated at the end of participant enrollment.

  5. Kappa statistics assessing agreement between the platelet reactivity measurements performed with the Multiplate® assay and the VASP and VerifyNow® assays in terms of identification of patients with low on-ticagrelor platelet reactivity. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]
    Blood samples will be collected collected in multiple time points in order to assess a broad range of platelet reactivity values. From each study participant, eight measurements of platelet reactivity (for all sampling points) for each compared methods will be included in the final analysis.The Kappa statistics values will be calculated at the end of participant enrollment.

  6. Correlation coefficient between the standardized values of platelet reactivity performed with the Multiplate® assay and the VASP and VerifyNow® assays. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess a broad range of platelet reactivity values. From each study participant, eight measurements of platelet reactivity (for all sampling points) for each compared methods will be included in the final analysis. Values of correlation coefficients will be calculated and compared among assessed methods of platelet reactivity measurement at the end of participant enrollment.

    Standardized platelet reactivity: actual platelet reactivity minus mean platelet reactivity divided by standardized deviation of the platelet reactivity.


  7. Intraclass correlation coefficient between the standardized values of platelet reactivity performed with the Multiplate® assay and the VASP and VerifyNow® assays. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess a broad range of platelet reactivity values. From each study participant, eight measurements of platelet reactivity (for all sampling points) for each compared methods will be included in the final analysis. Values of intraclass correlation coefficients will be calculated and compared among assessed methods of platelet reactivity measurement at the end of participant enrollment.

    Standardized platelet reactivity: actual platelet reactivity minus mean platelet reactivity divided by standardized deviation of the platelet reactivity.


  8. Blant-Altman analysis assessing agreement between the standardized values of platelet reactivity performed with the Multiplate® assay and the VASP and VerifyNow® assays. [ Time Frame: predose, 1, 2, 3, 4, 6, 12, 24 hours post-dose ]

    Blood samples will be collected in multiple time points in order to assess a broad range of platelet reactivity values. From each study participant, eight measurements of platelet reactivity (for all sampling points) for each compared methods will be included in the final analysis. Bland-Altman analysis will be performed at the end of participant enrollment.

    Standardized platelet reactivity: actual platelet reactivity minus mean platelet reactivity divided by standardized deviation of the platelet reactivity.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with myocardial infarction
Criteria

Inclusion Criteria:

  • provision of informed consent prior to any study specific procedures
  • diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
  • male or non-pregnant female, aged 18-80 years old
  • provision of informed consent for angiography and PCI

Exclusion Criteria:

  • treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
  • hypersensitivity to ticagrelor
  • current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
  • active bleeding
  • history of intracranial hemorrhage
  • recent gastrointestinal bleeding (within 30 days)
  • history of coagulation disorders
  • platelet count less than <100 x10^3/mcl
  • hemoglobin concentration less than 10.0 g/dl
  • history of moderate or severe hepatic impairment
  • history of major surgery or severe trauma (within 3 months)
  • patients considered by the investigator to be at risk of bradycardic events
  • second or third degree atrioventricular block during screening for eligibility
  • history of asthma or severe chronic obstructive pulmonary disease
  • patient required dialysis
  • manifest infection or inflammatory state
  • Killip class III or IV during screening for eligibility
  • respiratory failure
  • history of severe chronic heart failure (NYHA class III or IV)
  • concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
  • body weight below 50 kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02690454


Locations
Layout table for location information
Poland
Cardiology Department, Dr. A. Jurasz University Hospital
Bydgoszcz, Kujawsko-pomorskie, Poland, 85-094
Sponsors and Collaborators
Collegium Medicum w Bydgoszczy

Layout table for additonal information
Responsible Party: Marek Kozinski, Principal Investigator, Assoc. Prof., MD, PhD, FESC, Collegium Medicum w Bydgoszczy
ClinicalTrials.gov Identifier: NCT02690454     History of Changes
Other Study ID Numbers: CMUMK202E
First Posted: February 24, 2016    Key Record Dates
Last Update Posted: August 17, 2016
Last Verified: August 2016

Keywords provided by Marek Kozinski, Collegium Medicum w Bydgoszczy:
ticagrelor
ticagrelor active metabolite (AR-C124910XX)
platelet function tests
the flow cytometric VASP assay
the VerifyNow® device
the Multiplate® analyzer
pharmacokinetics
pharmacodynamics
Multiplate® ADPtest
VerifyNow® PRUTest™
Platelet VASP/P2Y12 assay

Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Coronary Artery Disease
Coronary Disease
Arterial Occlusive Diseases
Infarction
Myocardial Infarction
Ischemia
Necrosis
Myocardial Ischemia
Pathologic Processes
Arteriosclerosis
Ticagrelor
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs